Little Rock, ARNCT07911124Now EnrollingIRB Ready

Chronic Kidney Disease (CKD) Clinical Trial in Little Rock, AR

Access cutting-edge chronic kidney disease (ckd) treatment through this phase 2 clinical trial at a research site in Little Rock. Study-provided care at no cost to qualified participants.

Sponsored by University of Arkansas

Quick Self-Assessment

See if you qualify for this Little Rock location

Preparing your pre-screening questions…

Expert Care in Little Rock

Access chronic kidney disease (ckd) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related chronic kidney disease (ckd) treatment provided free

Apply for This Little Rock Location

Check if you qualify for this chronic kidney disease (ckd) clinical trial in Little Rock, AR

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Little Rock

    Convenient for AR residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Little Rock site if eligible
  4. 4Begin participation

About This Chronic Kidney Disease (CKD) Study in Little Rock

The goal of this clinical trial is to learn if treatment with ticagrelor tablets can decrease inflammation in patients with Chronic Kidney Disease (CKD). Inflammation is thought to contribute to the risk of heart disease which is the leading cause of death in patients with CKD. Decreasing inflammation may decrease the risk of heart disease. The main questions it aims to answer are: * Why are patients with CKD at increased risk for heart disease and how to reduce that risk in the future. * If there could be new treatment options for managing inflammation in blood of patients with CKD. Researchers will compare Ticagrelor to a Placebo (a look-alike substance that contains no drug) to see if ticagrelor decreases inflammation in adult patients with CKD. A comparator (control) group not receiving the drug/placebo will consist of adults without CKD. Participants with CKD will: * Take ticagrelor 90 mg or placebo orally twice daily for 42 days * Visit the clinic once every 2 weeks for checkups, tests, and bloodwork * Participation will last approximately 12 weeks Participants without CKD (control group) will visit the clinic twice (7 weeks apart) to provide information and bloodwork. Participation will last approximately 7 weeks with additional optional visits.

Sponsor: University of Arkansas

Who Can Participate

Inclusion Criteria

Population 1: CKD Participants
Provision of signed and dated written informed consent.
Age 21 to 75 years at the time of screening, inclusive.
Diagnosis of chronic kidney disease with estimated glomerular filtration rate (eGFR) \<45 ml/min/1.73m² as calculated by the CKD-EPI equation, confirmed from medical records or laboratory results.
Currently receiving the maximally tolerated or labeled dose of a renin-angiotensin-aldosterone system inhibitor (RAASi) as guideline-directed medical therapy (GDMT), or documentation of the reason for not receiving RAASi (e.g., intolerance, contraindication). Population 2: Control Participants
Provision of signed and dated written informed consent.
Age 21 to 75 years at the time of screening, inclusive.
Normal kidney function, defined as eGFR \>60 ml/min/1.73m² (CKD-EPI equation) and urinary albumin-to-creatinine ratio (UACR) \<30 mg/g, confirmed from medical records or laboratory results.

Exclusion Criteria

Population 1: CKD Participants
Unwilling or unable to participate in the protocol or comply with its components.
End-stage renal disease (defined as receiving peritoneal dialysis or hemodialysis) or any prior solid organ or bone marrow transplant. Rationale: dialysis directly affects platelet function and would confound the primary endpoint.
Acute kidney injury superimposed on CKD at the time of screening.
Acute coronary syndrome, acute myocardial infarction, or acute cerebrovascular event within 6 months prior to screening. Rationale: these participants are likely receiving P2Y12 inhibitor therapy, and their enrollment would confound the primary endpoint.
Hospitalization, major surgery, or use of systemic antibiotics within 1 month prior to screening. Rationale: these events are potentially associated with acute inflammatory changes that would confound baseline cytokine measurements.
Blood dyscrasias, active bleeding of any site, or a known bleeding diathesis.
History of gastrointestinal bleeding within 6 months prior to screening.
Concomitant use of any antiplatelet agent other than aspirin (e.g., clopidogrel, prasugrel, dipyridamole) or any antithrombotic or anticoagulant medication (e.g., warfarin, direct oral anticoagulants) at the time of screening or anticipated need during the study period.
Hemoglobin \<8 g/dL, white blood cell count \>20,000/μL, or platelet count \<50,000/μL at the time of screening.
Any active malignancy requiring systemic treatment, or chronic liver disease (including cirrhosis or hepatitis with active inflammation).
Current use of immunosuppressive medications (e.g., corticosteroids, calcineurin inhibitors, mycophenolate). Rationale: these medications independently alter cytokine profiles and leukocyte gene expression, confounding the primary and mechanistic endpoints.
Age older than 75 years. Rationale: individuals older than 75 years carry a substantially higher risk of bleeding on antiplatelet therapy and are excluded for participant safety.
Pregnancy or breastfeeding at the time of screening or plans to become pregnant during the study period. Women of reproductive potential will undergo a urine pregnancy test at screening (Visit 1); a positive result excludes from participation.
Known severe hypersensitivity or allergy to ticagrelor or any component of the study drug formulation.
Treatment with another investigational drug or other intervention ongoing, or within a month of randomization.
Ongoing treatment for infection. Population 2: Control Participants
Any known diagnosis of chronic kidney disease, eGFR ≤60 ml/min/1.73m², or UACR ≥30 mg/g.
Inability to sign consent and HIPAA form. Legal Authorized Representatives are not allowed to sign the consent form.
Unwillingness or inability to participate in the protocol or comply with any of its components.
Any current use of aspirin or NSAIDs and not willing to hold.
Current use of antibiotics or ongoing infection.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Little Rock?

Yes, this clinical trial (NCT07911124) has an active research site in Little Rock, AR that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Chronic Kidney Disease (CKD) Treatment Options in Little Rock, AR

If you're searching for chronic kidney disease (ckd) treatment options in Little Rock, AR, this clinical trial (NCT07911124) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Little Rock research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced chronic kidney disease (ckd) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all chronic kidney disease (ckd) clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Little Rock, AR

See all ankylosing spondylitis clinical trials recruiting in Little Rock — not just this study.

Browse Ankylosing Spondylitis Trials in Little Rock →

Ready to Join in Little Rock?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Little Rock, AR